Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128, BA.5: from 16 to 32, BQ.1.1: from 16 to 64 among the uninfected) influenced the effect of the fourth dose of vaccine on neutralizing antibodies. The fourth dose also increased binding antibodies (from 1036 BAU/mL to 5371 BAU/mL among the uninfected, from 3700 BAU/mL to 6773 BAU/mL among the BA.5 infected). This effect was less significant than that of the third dose of vaccine for both neutralizing (BA.2: from 8 to 128, BA.5: from 2 to 16, BA.2.75: from 8 to 64, BQ.1.1: from 2 to 16) and binding antibodies (from 139.8 BAU/mL to 2293 BAU/mL). However, the fourth dose attained the 5000 BAU/mL threshold conferring approximately 80% protection against a SARS-CoV-2 BA.2 infection in most individuals, unlike the third.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Vaccines - 11(2023), 6 vom: 12. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dimeglio, Chloé [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immune monitoring |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines11061095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358777941 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358777941 | ||
| 003 | DE-627 | ||
| 005 | 20231226075448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines11061095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358777941 | ||
| 035 | |a (NLM)37376484 | ||
| 035 | |a (PII)1095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dimeglio, Chloé |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128, BA.5: from 16 to 32, BQ.1.1: from 16 to 64 among the uninfected) influenced the effect of the fourth dose of vaccine on neutralizing antibodies. The fourth dose also increased binding antibodies (from 1036 BAU/mL to 5371 BAU/mL among the uninfected, from 3700 BAU/mL to 6773 BAU/mL among the BA.5 infected). This effect was less significant than that of the third dose of vaccine for both neutralizing (BA.2: from 8 to 128, BA.5: from 2 to 16, BA.2.75: from 8 to 64, BQ.1.1: from 2 to 16) and binding antibodies (from 139.8 BAU/mL to 2293 BAU/mL). However, the fourth dose attained the 5000 BAU/mL threshold conferring approximately 80% protection against a SARS-CoV-2 BA.2 infection in most individuals, unlike the third | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a immune monitoring | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vulnerable population | |
| 700 | 1 | |a Da-Silva, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Porcheron, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Panero, Marie-Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Staes, Laetitia |e verfasserin |4 aut | |
| 700 | 1 | |a Trémeaux, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Villars, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Izopet, Jacques |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 11(2023), 6 vom: 12. Juni |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:6 |g day:12 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines11061095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 6 |b 12 |c 06 | ||